Avenue Therapeutics Stock Investor Sentiment

ATXI Stock  USD 2.15  0.09  4.37%   
Under 56% of all Avenue Therapeutics' traders are looking to take a long position. The analysis of overall sentiment of trading Avenue Therapeutics stock suggests that some investors are interested at this time. Avenue Therapeutics' investing sentiment shows overall attitude of investors towards Avenue Therapeutics.
  

Avenue Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Avenue Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a week ago at www.macroaxis.com         
Acquisition by David Jin of 250000 shares of Avenue Therapeutics at 1.14 subject to Rule 16b-3
Macroaxis News
over two weeks ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Therapeutics Inc
Gurufocus Stories at Macroaxis
over two weeks ago at news.google.com         
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - G...
Google News at Macroaxis
over three weeks ago at investing.com         
Avenue Therapeutics director Jay Kranzler sells 136 in stock
Investing News at Macroaxis
over three weeks ago at news.google.com         
Avenue Therapeutics director Jay Kranzler sells 136 in stock - Investing.com
Google News at Macroaxis
over three weeks ago at www.macroaxis.com         
Disposition of tradable shares by Kranzler Jay D of Avenue Therapeutics at 2.24 subject to Rule 16b-...
Macroaxis News
over a month ago at www.macroaxis.com         
Acquisition by Paley Jeffrey of 14663 shares of Avenue Therapeutics subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Avenue Therapeutics to Participate in Maxim Groups 2024 Healthcare Virtual Summit
Yahoo News
over a month ago at globenewswire.com         
Avenue Therapeutics to Participate in Maxim Groups 2024 Healthcare Virtual Summit
Macroaxis News: globenewswire.com
over a month ago at news.google.com         
Avenue Therapeutics stock hits 52-week low at 2.17 - Investing.com
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Kranzler Jay D of 497 shares of Avenue Therapeutics at 2.5 subject to Rule 16b-3
Macroaxis News
over two months ago at news.google.com         
Avenue Therapeutics grants stock units to top executives By Investing.com - Investing.com Canada
Google News at Macroaxis
over two months ago at news.google.com         
Acquisition by Kranzler Jay D of tradable shares of Avenue Therapeutics at 2.4 subject to Rule 16b-3
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Acquisition by Oltmans Curtis Gale of 30000 shares of Avenue Therapeutics at 2.46 subject to Rule 16...
Macroaxis News
over two months ago at news.google.com         
Avenue Therapeutics stock hits 52-week low at 2.23 - Investing.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Avenue Therapeutics that are available to investors today. That information is available publicly through Avenue media outlets and privately through word of mouth or via Avenue internal channels. However, regardless of the origin, that massive amount of Avenue data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Avenue Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Avenue Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Avenue Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Avenue Therapeutics alpha.

Avenue Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Trading
09/09/2024
2
Acquisition by Charles Faith L. of 30000 shares of Avenue Therapeutics at 2.46 subject to Rule 16b-3
09/23/2024
3
Acquisition by Oltmans Curtis Gale of 30000 shares of Avenue Therapeutics at 2.46 subject to Rule 16b-3
09/25/2024
4
Acquisition by Kranzler Jay D of tradable shares of Avenue Therapeutics at 2.4 subject to Rule 16b-3
09/27/2024
5
Acquisition by Kranzler Jay D of 497 shares of Avenue Therapeutics at 2.5 subject to Rule 16b-3
09/30/2024
6
Avenue Therapeutics stock hits 52-week low at 2.17 - Investing.com
10/04/2024
7
Acquisition by Paley Jeffrey of 14663 shares of Avenue Therapeutics subject to Rule 16b-3
10/11/2024
8
Disposition of tradable shares by Kranzler Jay D of Avenue Therapeutics at 2.24 subject to Rule 16b-3
11/05/2024
9
Avenue Therapeutics director Jay Kranzler sells 136 in stock
11/08/2024
10
Acquisition by David Jin of 250000 shares of Avenue Therapeutics at 1.14 subject to Rule 16b-3
11/22/2024

Complementary Tools for Avenue Stock analysis

When running Avenue Therapeutics' price analysis, check to measure Avenue Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avenue Therapeutics is operating at the current time. Most of Avenue Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avenue Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avenue Therapeutics' price. Additionally, you may evaluate how the addition of Avenue Therapeutics to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
FinTech Suite
Use AI to screen and filter profitable investment opportunities